SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : GZTC
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Steve Push who wrote (347)7/9/1997 3:02:00 PM
From: biowa   of 752
 
Steve,

PseudoBiologist has found a Financial Times ft.com article (7/5/97) which seems to clarify the PPL Therapeutics story. It seems they are only talking one component at a time, presumably under native mammary promoter control and not making bulk plasma. However, this story suggests a rather aggressive approval timeline for PPL's first product:

>>The first protein to be produced in this way should be Factor IX, the treatment for haemophiliacs. A flock of sheep containing it in their milk could be born next spring; the drug could be submitted to health regulators in 1999 and be on the market in 2000.<<

From your perspective, does this seem like a reasonable approval timeline for a transgenic protein, even in an established indication? Two years to market would have to be record, even in Europe.

Also the story suggests that PPL wants to move into cattle. How tight is your patent estate on this (excluding the Pharming cross-license)?

Hope your trip to Europe was profitable and pleasant,
biowa
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News